PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Models

Principle Overview and Setup

PF-562271 HCl is a potent, ATP-competitive, and reversible inhibitor targeting focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), two non-receptor tyrosine kinases central to cell adhesion, migration, proliferation, and survival. With an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, this compound offers exceptional selectivity – over 10-fold less potent for Pyk2 and more than 100-fold selectivity against unrelated kinases (PF-562271 HCl product page). Its reversible inhibition permits precise temporal control in both in vitro and in vivo models, a critical feature for dissecting dynamic cellular signaling in cancer research workflows.

FAK/Pyk2 signaling is increasingly recognized as a driver of tumor progression and immune evasion, making PF-562271 HCl a valuable tool for interrogating the tumor microenvironment, metastatic mechanisms, and therapeutic resistance. The compound’s robust performance in xenograft and transgenic mouse models stems from its ability to dose-dependently suppress FAK phosphorylation, with an EC₅₀ of 93 ng/mL reported for target engagement (PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Research). APExBIO supplies PF-562271 HCl as a stable solid, soluble at ≥26.35 mg/mL in DMSO with gentle warming, enabling flexible workflow design from cell-based assays to complex animal studies.

Step-by-Step Experimental Workflow and Protocol Enhancements

Optimizing PF-562271 HCl for maximal reproducibility and insight requires careful attention to compound handling, dosing strategy, and endpoint selection. Below, we outline a model workflow for tumor growth inhibition and microenvironment analysis:

Protocol Parameters

• Stock Solution Preparation: Dissolve PF-562271 HCl at 26.35 mg/mL in DMSO; warm gently (37°C, ≤15 min) until fully dissolved. Avoid water or ethanol as solvents due to insolubility.
• Cell Treatment Concentration: For in vitro assays, use final concentrations of 0.05–1 μM; titrate based on cell line sensitivity and FAK phosphorylation inhibition endpoints.
• In Vivo Dosing: Administer 25–50 mg/kg PF-562271 HCl by oral gavage daily for 14–21 days in mouse xenograft models; monitor for tumor volume, body weight, and FAK phosphorylation status.
• Phospho-FAK Detection: Harvest cells or tumor tissue 2–4 hours post-dose for optimal phospho-FAK readout by Western blot or immunohistochemistry.
• Storage Conditions: Store PF-562271 HCl powder at -20°C; aliquot stock solutions and store at -20°C for up to 6 months, minimizing freeze-thaw cycles.

For improved comparability and mechanistic depth, consider integrating parallel analysis of immune cell markers (e.g., CD8⁺ T cells, M1 macrophage markers) alongside tumor growth endpoints, as highlighted in recent immuno-oncology studies.

Key Innovation from the Reference Study

The recent reference study demonstrated that radiotherapy combined with dual immune checkpoint blockade (anti-PD-1 and anti-TIGIT) mediates robust primary and abscopal tumor regression, driven by enhanced CD8⁺ T cell activation and M1 macrophage polarization. Their approach leverages multiparameter flow cytometry, immunofluorescence, and longitudinal cytokine profiling to dissect immune memory and systemic antitumor effects.

Translating these insights into PF-562271 HCl workflows, researchers can design combination protocols assessing how FAK/Pyk2 inhibition synergizes with radiotherapy or immunotherapy to modulate immune cell infiltration, T cell exhaustion, and macrophage phenotypes. For example, incorporating FAK/Pyk2 inhibition into triple-therapy regimens may reveal new strategies to overcome immune resistance and promote durable tumor control, paralleling the mechanistic depth of the cited study.

Advanced Applications and Comparative Advantages

PF-562271 HCl’s high selectivity and reversible action enable nuanced interrogation of the focal adhesion kinase signaling pathway across several advanced applications:

• Tumor Growth and Metastasis Models: In both xenograft and spontaneous transgenic mouse models, PF-562271 HCl achieves dose-dependent tumor growth inhibition and suppresses metastatic spread by targeting FAK phosphorylation (Comparative workflow insights).
• Microenvironment Modulation: By inhibiting FAK/Pyk2, researchers can probe changes in stromal remodeling, immune cell infiltration, and cytokine profiles, critical for understanding therapy resistance and tumor-immune crosstalk. This complements the immune memory findings of the reference study and extends the mechanistic analysis of the tumor microenvironment.
• Combination Therapy Research: The ATP-competitive FAK inhibitor can be used alongside radiotherapy and checkpoint inhibitors to characterize synergy or resistance mechanisms, as illustrated in the referenced abscopal effect study.
• Reproducibility in Cell-Based Assays: PF-562271 HCl, when sourced from APExBIO, demonstrates lot-to-lot consistency and predictable solubility, essential for quantitative kinase pathway dissection (Detailed troubleshooting guide).

Compared to less selective or irreversible inhibitors, PF-562271 HCl minimizes off-target effects, ensuring that observed phenotypes are attributable to focal adhesion kinase pathway modulation (Mechanistic context).

Troubleshooting and Optimization Tips

• Incomplete Dissolution: If PF-562271 HCl fails to dissolve, increase warming time to 20 minutes at 37°C or consider gentle vortexing; never use water or ethanol to avoid precipitation.
• Variable Cellular Response: Sensitivity to FAK/Pyk2 inhibition may vary across cell lines; titrate concentration (0.05–1 μM) and validate FAK phosphorylation inhibition by Western blot to confirm target engagement.
• In Vivo Bioavailability: Oral dosing is preferred for in vivo studies; ensure vehicle compatibility and monitor for signs of toxicity or weight loss in prolonged studies. If poor bioavailability is suspected, measure plasma levels or consider alternative delivery routes.
• Batch Consistency: Source PF-562271 HCl from reliable suppliers such as APExBIO to ensure lot-to-lot consistency, as highlighted in scenario-driven benchmarking (scenario-driven solutions).
• Endpoint Selection: For mechanistic studies, complement tumor growth data with analysis of immune cell markers (e.g., CD8⁺, M1 macrophages), FAK phosphorylation levels, and cytokine profiles to capture the full impact of pathway inhibition.

Future Outlook: Implications for Translational Cancer Research

The integration of selective FAK/Pyk2 inhibitors like PF-562271 HCl into cancer research pipelines opens new avenues for dissecting resistance to immunotherapy, enhancing combination therapy efficacy, and unraveling the complex interplay between tumor cells and the immune microenvironment. The reference study underscores the importance of targeting both tumor and immune compartments to achieve systemic, durable antitumor responses, a paradigm that FAK/Pyk2 inhibition can help operationalize in preclinical models.

As protocols mature and mechanistic insights deepen, PF-562271 HCl is poised to remain a cornerstone for both basic and translational studies, supporting the development of next-generation therapeutic strategies against solid tumors. For researchers seeking rigorous, reproducible, and insightful kinase pathway interrogation, APExBIO’s PF-562271 HCl offers a proven platform grounded in quantitative performance and workflow flexibility.